Advanced Therapy Medicinal Products Market Competitive Landscape and Industry Expansion Strategies By 2026
Advanced
Therapy Medicinal Products (ATMPs) are innovative therapies
that comprises cell therapy, gene therapy, and tissue engineered
products. Cell therapy products include cellular immunotherapies and
autologous and allogeneic cells for certain therapeutic indications
including adult and embryonic stem cells. Whereas, Human gene therapy
refers to products that introduce genetic material into individuals
DNA to replace faulty or missing genetic material, thus treating a
disease or abnormal medical condition. These are a novel class of
medicines that offer potential treatment opportunities for diseases
that have currently limited or no therapeutic options such as
hemophilia, cystic fibrosis, metabolic disorders, muscular
dystrophies, skin burns, Alzheimer, and cancer. Although majority of
ATMPs are in an early stage of development, consolidated trial stage
and the chances to cure chronic conditions signify that ATMPs may
achieve the market sooner than standard treatments. Furthermore,
advanced therapy medicinal products are regulated and authorized for
marketing by the Food and Drug Administration (FDA) in the U.S. and
by European Medicines Agency (EMA) in the Europe.
Rising incidences
of Alzheimer’s is expected to foster the growth of advanced therapy
medicinal products market
The factors that are
contributing the growth of advanced therapy medicinal products market
are rising prevalence of Alzheimer’s disease. According to
Alzheimer’s disease International in 2017, around 50 million people
were estimated to suffer from Alzheimer’s disease across the globe.
Furthermore, rising demand for gene therapies used in the treatment
of ocular, neurodegenerative diseases, and several cancers
accompanied by technological advancements in genetic engineering tool
such as RNAi are the factors that are expected to boost the growth
of advanced therapy medicinal products market. However, the factors
that are hindering the growth of advanced medicinal therapy products
market are inadequate transparency, lack of funds, and regulatory
guidance for biopharmaceutical companies to manufacture these
therapies and products.
Advanced Therapy
Medicinal Products Market Taxonomy:
Advanced therapy
medicinal products are segmented on the basis of therapy, diseases,
and geography
On the basis of
products, the global advanced therapy medicinal products market are
segmented into:
Somatic Cell
Therapy Medicinal Products
Tissue
Engineered Medicinal Products
Gene Therapy
Medicinal Products
On the basis of
diseases, the global advanced therapy medicinal products market are
segmented into:
Alzheimer’s
Cystic Fibrosis
Muscular
Dystrophies
Hemophilia
On the basis of
geography, the global advanced medicinal therapy products are
segmented into North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa. North America is expected to hold a dominant
position in the global advanced medicinal therapy products market,
owing to the development in the field of cell and gene therapy. For
instance, the innovative gene therapy known as CAR-T or chimeric
antigen receptor T-cell therapy harnesses the body’s own immune
cells to recognize and attack malignant cells. The T-cells are
harvested and modified with a new gene. The new gene contains a
protein that directs the T-cells to target and kill leukemia cells
that have a specific antigen on the surface. Moreover, Food and Drug
Administration (FDA) approved first gene therapy in the U.S. in 2017,
leading a new approach to the treatment of cancer and other serious
and life-threatening diseases. Moreover, Kymriah a cell based gene
therapy has also been approved by FDA in 2017 in the U.S. for the
treatment of patients with a form of acute lymphoblastic leukemia.
Furthermore, Asia Pacific is expected to be the fastest growing
region for the global advanced therapy medicinal products market
mainly due to rising number of skin burns cases and cancer diseases.
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1101
Strategic
acquisitions by Pfizer to develop gene therapies for the treatment of
neuromuscular conditions to enhance the competitive environment
The key players
operating the advanced therapy medicinal products market include
Uniqure, Pfizer, Bluebird Bio Inc., BioMarin Pharmaceutical, Novartis
AG, GE Healthcare, Shire Biotechnology, and Kite Pharma. The key
players are focusing on strategic mergers and acquisition and
development of innovative products. For instance, Pfizer acquired
Bamboo Therapeutics, a biotechnology company focused on developing
gene therapies for the treatment of patients with diseases related to
neuromuscular conditions and the diseases affecting central nervous
system. The acquisition is expected to significantly expand Pfizer’s
expertise in gene therapy by providing clinical and pre-clinical
assets to balance the rare disease portfolio of company with advanced
recombinant Adeno Associated Virus vector design and production
technology, which is fully functional phase I/II gene therapy with
manufacturing facilities.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment